scholarly journals Cloning recombinant consensus interferon with overlap extension polymerase chain reaction

2008 ◽  
Vol 16 (5) ◽  
pp. 479
Author(s):  
Shun-Ai Liu ◽  
Ryutaro Asano ◽  
Jing-Jing Guo ◽  
Zhi-Ying Liu ◽  
Kang-Kang Yu ◽  
...  
2018 ◽  
Vol 2018 (8) ◽  
pp. pdb.prot097758 ◽  
Author(s):  
Matteo Forloni ◽  
Alex Y. Liu ◽  
Narendra Wajapeyee

Author(s):  
Fatemeh Khademi ◽  
Pantea Mohammadi ◽  
Ali Mostafaei

Despite the unparalleled success of anti-CD20-targeted immunotherapy, the currently available mAbs are not sufficiently efficacious in the treatment of lymphoma. 1F5 is one of a panel of anti-CD20 mAbs that was used in the B-cell lymphoma serotherapy. Despite the efficacy of murine 1F5 mAbs in lymphoma patients, the 1F5 chimeric antibodies with human effector functionality are yet to be approved and widely used in the treatment of lymphoma. In this study, the conversion of 1F5 mAb from mouse IgG2a to human-mouse chimeric IgG1 was achieved and the chimeric antibody was partially characterized. We constructed the 1F5 chimeric mouse-human anti-CD20 antibody genes using an efficient Splicing by overlap extension-polymerase chain reaction (SOE-PCR) technique and cloned the chimeric heavy and light genes in pBudCE4.1 mammalian expression vector, followed by purification of the expressed chimeric 1F5 mAbs using affinity chromatography. Our investigation also included the biological properties of purified chimeric antibodies. The generated 1F5 chimeric mAbs mediate complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) against Raji and Daudi Burkitt's lymphoma cell lines, which were comparable with rituximab and exhibit superior reduction in cell viability in vitro, compared to rituximab. The current study indicated that the generated chimeric 1F5 mAbs has potential CDC and ADCC activity which was comparable with rituximab whereas it exhibits a superior reduction in cell viability, compared to rituximab. Our work contributes to future studies involving in vivo biological functions and the application of the 1F5 chimeric antibody.


2012 ◽  
Vol 429 (1) ◽  
pp. 76-78 ◽  
Author(s):  
Huilin Wei ◽  
Jie Hu ◽  
Lin Wang ◽  
Feng Xu ◽  
ShuQi Wang

Gene ◽  
1989 ◽  
Vol 77 (1) ◽  
pp. 51-59 ◽  
Author(s):  
Steffan N. Ho ◽  
Henry D. Hunt ◽  
Robert M. Horton ◽  
Jeffrey K. Pullen ◽  
Larry R. Pease

BioTechniques ◽  
2013 ◽  
Vol 54 (3) ◽  
Author(s):  
Robert M. Horton ◽  
Zeling Cai ◽  
Steffan N. Ho ◽  
Larry R. Pease

Author(s):  
G. W. Hacker ◽  
I. Zehbe ◽  
J. Hainfeld ◽  
A.-H. Graf ◽  
C. Hauser-Kronberger ◽  
...  

In situ hybridization (ISH) with biotin-labeled probes is increasingly used in histology, histopathology and molecular biology, to detect genetic nucleic acid sequences of interest, such as viruses, genetic alterations and peptide-/protein-encoding messenger RNA (mRNA). In situ polymerase chain reaction (PCR) (PCR in situ hybridization = PISH) and the new in situ self-sustained sequence replication-based amplification (3SR) method even allow the detection of single copies of DNA or RNA in cytological and histological material. However, there is a number of considerable problems with the in situ PCR methods available today: False positives due to mis-priming of DNA breakdown products contained in several types of cells causing non-specific incorporation of label in direct methods, and re-diffusion artefacts of amplicons into previously negative cells have been observed. To avoid these problems, super-sensitive ISH procedures can be used, and it is well known that the sensitivity and outcome of these methods partially depend on the detection system used.


Sign in / Sign up

Export Citation Format

Share Document